PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia

Lignende værker

• Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis
  af: Paniagua, Ricardo T., et al.
  Udgivet: (2006)
• Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412
  af: Growney, Joseph D., et al.
  Udgivet: (2005)
• Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance
  af: Tseng, Ping-Hui, et al.
  Udgivet: (2005)
• Loss of p53 impedes the antileukemic response to BCR-ABL inhibition
  af: Wendel, Hans-Guido, et al.
  Udgivet: (2006)
• Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate
  af: Reichardt, P, et al.
  Udgivet: (2004)